Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Infectious Disease Implementation Research

The Infectious Disease Implementation Research Team is a multi-disciplinary group researching the best way to implement infectious disease prevention and treatment strategies to improve the wellbeing of children and teenagers.

The Infectious Disease Implementation Research team is developing and implementing better ways to observe and evaluate the effectiveness of public health programs, including optimising treatment for both acute and complex diseases and  exploring new strategies through disease modelling and analytics - providing real-world results that are immediately applicable.

The team uses a range of methods to conduct their research, including pragmatic and adaptive clinical trials, observational comparative effectiveness studies and data linkage studies, causal network and transmission modelling and learning health systems research.

Focusing on common and serious childhood infections such as gastroenteritis, serious bacterial infections and cystic fibrosis exacerbations, the Implementation Research team are looking at new and innovative clinical trial methods and analytic approaches for evaluating treatments. This includes examining their effectiveness by embedding research in the clinical settings they are intended to be used, and working on projects to gauge efficacy of new and existing preventions and treatments in a way that has never been done before in Australia.

Collaborating widely, the team works with clinicians, policy makers, epidemiologists, statisticians and importantly, community members, to help ensure their research is efficient, sustainable and responsive to clinical, community and policy needs. The team also work in close collaboration with other research groups around Australia, including the University of Sydney’s Health and Clinical Analytics Team, particularly to support many studies that are underway at sites outside of Western Australia.

Team Highlights

In 2019, the Implementation Reseatch team were successful in securing major funding for:

  • Randomised controlled trial of mixed whole-cell/acellular pertussis vaccination versus acellular-only vaccination of infants (GNT1158722, NHMRC project grant, 2019-2023, $3.9million)
  • Adaptive Trial of Messaging to Improve Vaccine Coverage (AuTOMATIC), (Ramaciotti Health investment grant, 2020-22, $280,000)
  • Collaborative project 'Better health through better trials: a national network to develop and implement innovative clinical trials methodology'. (GNT1171422, NHMRC Centres of Research Excellence, 2019-2024, $2.4million)

The Implementation Research team shared its ideas and results to several audiences across a range of mediums, including:

  • providing educational seminars to students, researchers and clinical trialists throughout Australia
  • launching the Adaptive Health Intelligence website to optimise further collaborative opportunities
  • holding consumer workshops for individuals living with cystic fibrosis and hepatitis C.

Team leader

Professor Tom Snelling
Professor Tom Snelling

BMBS DTMH GDipClinEpid PhD FRACP

Head, Infectious Disease Implementation Research

Team members (15)

Danielle Darragh

Danielle Darragh

Program Manager, Infectious Disease Implementation Research

Julie Marsh

Julie Marsh

Biostatistical Lead

Michael Dymock

Michael Dymock

Biostatistician, PhD Student

Nelly Newall

Nelly Newall

Clinical Trial Co-ordinator

Jessica Ramsay

Jessica Ramsay

Clinical Research Coordinator – Casual

Reena D’Souza

Reena D’Souza

Project Manager

Kylie Rogers

Kylie Rogers

Data Manager

Mitch Messer

Mitch Messer

Consumer Advisor

Charlie McLeod

Charlie McLeod

Clinical Research Officer

Evelyn Tay

Evelyn Tay

Biostatistician

Ariel Mace

Ariel Mace

PhD Student

Carly McCallum

Carly McCallum

Clinical Research Manager

Ada Parry

Ada Parry

Cultural Advisor

Edward Pan

Edward Pan

Statistical Programmer

George Salama

George Salama

Clinical Trial Coordinator

Infectious Disease Implementation Research

Resources

Reports and Findings

Reports and Findings

The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocol

Coronavirus-2019 (COVID-19) vaccination in Australia commenced in February 2021. The first vaccines recommended for use were AZD1222 and BNT162b2, both delivered as a two-dose primary schedule. In the absence of sustained immunity following immunisation, recommendations for booster vaccination have followed. It is likely that periodic boosting will be necessary for at least some Australians, but it is unknown what the optimal booster vaccines and schedules are or for whom vaccination should be recommended. 

The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.

Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol

Staphylococcus aureus bloodstream infection is traditionally treated with at least 2 weeks of intravenous antibiotics in adults, 3-7 days in children, and often longer for those with complicated disease. The current practice of treating S. aureus bacteremia with prolonged IV antibiotics (rather than oral antibiotics) is based on historical observational research and expert opinion. Prolonged IV antibiotic therapy has significant disadvantages for patients and healthcare systems, and there is growing interest in whether a switch to oral antibiotics following an initial period of IV therapy is a safe alternative for clinically stable patients.

Trimodal skin health programme for childhood impetigo control in remote Western Australia (SToP): a cluster randomised, stepped-wedge trial

Skin infections affect physical health and, through stigma, social-emotional health. When untreated, they can cause life-threatening conditions. We aimed to assess the effect of a holistic, co-designed, region-wide skin control programme on the prevalence of impetigo.

Show all